Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: J Immunol. 2009 Apr 1;182(7):4289–4295. doi: 10.4049/jimmunol.0803736

Figure 3.

Figure 3

Induction of CYP27b1 expression and activity following TLR activation of monocytes cultured in autologous serum conditions. A. Changes in CYP27b1 expression following treatment with ligands to TLR2/1 (19 kDa lipopeptide, 1 ng/ml) or TLR4 (lipopolysaccharide, 100 ng/ml), in monocytes cultured in medium supplemented with autologous serum with or without added 25OHD. Data shown are the mean fold-change in CYP27b1 mRNA expression relative to vehicle-treated cells based on mean ± SD ΔCt values for each different. B) Changes in VDR expression following treatment with ligands to TLR2 in monocytes cultured in medium supplemented with autologous serum with or without added 25OHD. Data shown are the mean fold-change in VDR mRNA expression relative to vehicle-treated cells based on mean ± SD ΔCt values for each different treatment. C) Changes in monocytes synthesis of 1,25(OH)2D following treatment with ligand to TLR2, in the presence or absence of added 25OHD. * = mean ΔCT values statistically different to ΔCT value for vehicle-treated control monocytes, p<0.05. ** = mean ΔCT values statistically different to ΔCT value for vehicle-treated control monocytes, p<0.01. *** = mean dCT values statistically different to ΔCT value for vehicle-treated control monocytes, p<0.001. # = level of 1,25(OH)2D statistically different from TLR-treated control p<0.05. # = level of 1,25(OH)2D statistically different from vehicle-treated control p<0.01.